vs
Side-by-side financial comparison of Dominari Holdings Inc. (DOMH) and UroGen Pharma Ltd. (URGN). Click either name above to swap in a different company.
UroGen Pharma Ltd. is the larger business by last-quarter revenue ($37.8M vs $30.1M, roughly 1.3× Dominari Holdings Inc.). On growth, Dominari Holdings Inc. posted the faster year-over-year revenue change (220.4% vs 54.0%). Over the past eight quarters, Dominari Holdings Inc.'s revenue compounded faster (369.1% CAGR vs 41.9%).
UroGen Pharma Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urological diseases and specialty cancers. Its core offerings target unmet medical needs for conditions including non-muscle invasive bladder cancer, with primary operations and sales markets across North America and Europe.
DOMH vs URGN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $30.1M | $37.8M |
| Net Profit | $-131.8M | — |
| Gross Margin | — | 91.3% |
| Operating Margin | -8.9% | -50.5% |
| Net Margin | -438.1% | — |
| Revenue YoY | 220.4% | 54.0% |
| Net Profit YoY | -12426.2% | — |
| EPS (diluted) | $-6.94 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.1M | $37.8M | ||
| Q3 25 | $50.8M | $27.5M | ||
| Q2 25 | $34.1M | $24.2M | ||
| Q1 25 | $8.1M | $20.3M | ||
| Q4 24 | $9.4M | $24.6M | ||
| Q3 24 | $4.0M | $25.2M | ||
| Q2 24 | $6.2M | $21.8M | ||
| Q1 24 | $1.4M | $18.8M |
| Q4 25 | $-131.8M | — | ||
| Q3 25 | $125.2M | $-33.3M | ||
| Q2 25 | $16.6M | $-49.9M | ||
| Q1 25 | $-32.5M | $-43.8M | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $-4.2M | $-23.7M | ||
| Q2 24 | $-6.1M | $-33.4M | ||
| Q1 24 | $-5.4M | $-32.3M |
| Q4 25 | — | 91.3% | ||
| Q3 25 | — | 88.1% | ||
| Q2 25 | — | 85.3% | ||
| Q1 25 | — | 88.5% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 90.3% | ||
| Q2 24 | — | 89.8% | ||
| Q1 24 | — | 90.8% |
| Q4 25 | -8.9% | -50.5% | ||
| Q3 25 | -3.1% | -99.7% | ||
| Q2 25 | -57.0% | -171.2% | ||
| Q1 25 | -394.6% | -182.3% | ||
| Q4 24 | 0.4% | -112.6% | ||
| Q3 24 | -79.1% | -69.6% | ||
| Q2 24 | -44.3% | -118.3% | ||
| Q1 24 | -205.2% | -137.1% |
| Q4 25 | -438.1% | — | ||
| Q3 25 | 246.4% | -121.3% | ||
| Q2 25 | 48.7% | -206.2% | ||
| Q1 25 | -400.5% | -216.5% | ||
| Q4 24 | 11.4% | — | ||
| Q3 24 | -104.2% | -93.9% | ||
| Q2 24 | -99.1% | -152.9% | ||
| Q1 24 | -398.0% | -171.9% |
| Q4 25 | $-6.94 | — | ||
| Q3 25 | $7.27 | — | ||
| Q2 25 | $1.12 | — | ||
| Q1 25 | $-3.02 | — | ||
| Q4 24 | $0.21 | — | ||
| Q3 24 | $-0.67 | — | ||
| Q2 24 | $-1.01 | — | ||
| Q1 24 | $-0.91 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.5M | $160.1M |
| Total DebtLower is stronger | — | $125.0M |
| Stockholders' EquityBook value | $69.4M | $-105.5M |
| Total Assets | $112.9M | $200.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.5M | $160.1M | ||
| Q3 25 | $176.2M | $153.8M | ||
| Q2 25 | $28.2M | $176.0M | ||
| Q1 25 | $18.9M | $216.1M | ||
| Q4 24 | $8.2M | $282.7M | ||
| Q3 24 | $7.2M | $278.9M | ||
| Q2 24 | $12.1M | $272.3M | ||
| Q1 24 | $7.1M | $183.2M |
| Q4 25 | — | $125.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $69.4M | $-105.5M | ||
| Q3 25 | $210.2M | $-115.4M | ||
| Q2 25 | $88.6M | $-93.4M | ||
| Q1 25 | $42.4M | $-46.5M | ||
| Q4 24 | $39.9M | $-8.8M | ||
| Q3 24 | $38.3M | $25.5M | ||
| Q2 24 | $42.4M | $30.3M | ||
| Q1 24 | $47.7M | $-40.1M |
| Q4 25 | $112.9M | $200.5M | ||
| Q3 25 | $223.4M | $185.0M | ||
| Q2 25 | $109.3M | $208.7M | ||
| Q1 25 | $52.3M | $247.6M | ||
| Q4 24 | $47.1M | $285.7M | ||
| Q3 24 | $43.4M | $301.9M | ||
| Q2 24 | $49.1M | $281.8M | ||
| Q1 24 | $52.2M | $200.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $22.7M | $-38.3M |
| Free Cash FlowOCF − Capex | — | $-38.3M |
| FCF MarginFCF / Revenue | — | -101.3% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-162.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.7M | $-38.3M | ||
| Q3 25 | $-4.9M | $-42.3M | ||
| Q2 25 | $-353.0K | $-39.8M | ||
| Q1 25 | $1.2M | $-42.0M | ||
| Q4 24 | $-16.7M | $-13.6M | ||
| Q3 24 | $-4.7M | $-27.7M | ||
| Q2 24 | $1.4M | $-23.7M | ||
| Q1 24 | $-8.6M | $-31.7M |
| Q4 25 | — | $-38.3M | ||
| Q3 25 | — | $-42.4M | ||
| Q2 25 | — | $-40.0M | ||
| Q1 25 | — | $-42.1M | ||
| Q4 24 | — | $-13.7M | ||
| Q3 24 | — | $-27.8M | ||
| Q2 24 | — | $-23.8M | ||
| Q1 24 | — | — |
| Q4 25 | — | -101.3% | ||
| Q3 25 | — | -154.1% | ||
| Q2 25 | — | -165.0% | ||
| Q1 25 | — | -207.7% | ||
| Q4 24 | — | -55.9% | ||
| Q3 24 | — | -110.1% | ||
| Q2 24 | — | -109.1% | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | — | 0.6% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 0.4% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | — | ||
| Q2 25 | -0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -15.65× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
URGN
| Jelmyto | $23.8M | 63% |
| Other | $14.0M | 37% |
